- Nov 2022
-
-
As Beschizza said …“I wanted something where people could publish their thoughts without any false game of social manipulation, one-upmanship, and favor-trading.”It was, as I called it, “antiviral design”.
Definition of "antiviral design"
Later, Thompson says: "[Mastodon] was engineered specifically to create _friction — _to slow things down a bit. This is a big part of why it behaves so differently from mainstream social networks."
The intentional design decisions on Mastodon slow user activity.
-
- Aug 2022
-
www.nature.com www.nature.com
-
Kozlov, M. (2022). Why scientists are racing to develop more COVID antivirals. Nature, 601(7894), 496–496. https://doi.org/10.1038/d41586-022-00112-8
-
-
www.nature.com www.nature.com
-
Meng, B., Abdullahi, A., Ferreira, I. A. T. M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P. P., Fatihi, S., Rathore, S., Zepeda, S. K., Papa, G., Kemp, S. A., Ikeda, T., Toyoda, M., Tan, T. S., Kuramochi, J., Mitsunaga, S., Ueno, T., … Gupta, R. K. (2022). Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature, 1–1. https://doi.org/10.1038/s41586-022-04474-x
-
- Mar 2022
-
www.cnn.com www.cnn.com
-
CNN, A. S. (n.d.). Pfizer begins Phase 2 and 3 trial of Covid-19 antiviral Paxlovid in children ages 6 to 17. CNN. Retrieved 22 March 2022, from https://www.cnn.com/2022/03/09/health/pfizer-paxlovid-pediatric-trial/index.html
-
- Feb 2022
-
-
Mancini, D. P., & Smyth, J. (2022, February 16). Merck struggles to win European approval for Covid-19 antiviral pill. Financial Times. https://www.ft.com/content/2cf0b6cc-b07b-4ff9-a833-42eb1798a576
-
-
assets.publishing.service.gov.uk assets.publishing.service.gov.uk
-
Academics: Viral Evolution Scenarios, 10 February 2022. (n.d.). GOV.UK. Retrieved February 14, 2022, from https://www.gov.uk/government/publications/academics-viral-evolution-scenarios-10-february-2022
Tags
- testing
- vaccine efficacy
- surveillance
- UK
- vaccine
- variant
- immune escape
- therapeutic
- is:report
- transmissibility
- prediction
- vaccination
- COVID-19
- heterogeneity
- protection
- scenario
- antigenic escape
- infection
- immunity
- antiviral drug resistance
- lang:en
- viral evolution
- waning immunity
- severity
Annotators
URL
-
-
twitter.com twitter.com
-
Anthony J Leonardi, PhD, MS. (2022, January 22). Wow. This is concerning. H/t @ForesightWisdom it is learning to become more chronic. Https://t.co/XwFR4D0kiy [Tweet]. @fitterhappierAJ. https://twitter.com/fitterhappierAJ/status/1484996537889476610
-
- Jan 2022
-
medicalxpress.com medicalxpress.com
-
Tong-Hyung, K. (n.d.). South Korea gets first supply of Pfizer’s COVID-19 pills. Retrieved January 20, 2022, from https://medicalxpress.com/news/2022-01-south-korea-pfizer-covid-pills.html
-
- Dec 2021
-
-
Mahase, E. (2021). Covid-19: Do vaccines work against omicron—and other questions answered. BMJ, 375, n3062. https://doi.org/10.1136/bmj.n3062
Tags
- Omicron
- research
- response
- testing
- Africa
- travel ban
- UK
- variant
- booster
- COVID-19
- antiviral
- delta
- PCR
- antibody
- lang:en
- detection
- EU
- epidemiology
- Europe
- severity
- data
- restrictions
- work from home
- is:article
- vaccine
- transmissibility
- infection rate
- domestic measures
- hospitalization
- mutation
- mask wearing
- reinfection
- modeling
- South Africa
- risk
- treatment
Annotators
URL
-
- Nov 2021
-
www.theguardian.com www.theguardian.com
-
France-Presse, A. (2021, November 17). Pfizer strikes deal to allow generic versions of its Covid pill for world’s poor. The Guardian. https://www.theguardian.com/business/2021/nov/17/pfizer-strikes-deal-to-allow-generic-versions-of-its-covid-pill-for-worlds-poor
Tags
- Paxlovid
- antiviral pill
- approval
- Pfizer
- manufacturer
- income
- public health emergency
- cost
- royalty
- lang:en
- vaccine
- funding
- COVID-19
- is:news
- treatment
Annotators
URL
-
-
www.science.org www.science.org
-
Couzin-Frankel, J. (2021). Antiviral pills could change pandemic’s course. Science, 374(6569), 799–800. https://doi.org/10.1126/science.acx9605
-
- Oct 2021
-
www.researchsquare.com www.researchsquare.com
-
Divergent trajectories of antiviral memory after SARS-Cov-2 infection. (2021, June 15). https://doi.org/10.21203/rs.3.rs-612205/v1
-
- Sep 2021
-
www.bmj.com www.bmj.com
-
Stokel-Walker, C. (2021). The search for antivirals for covid-19. BMJ, 374, n2165. https://doi.org/10.1136/bmj.n2165
-
- Sep 2020
-
pittsburgh.cbslocal.com pittsburgh.cbslocal.com
-
University Of Pittsburgh Scientists Discover Biomolecule That May Neutralize Coronavirus. (2020, September 15). https://pittsburgh.cbslocal.com/2020/09/15/coronavirus-university-pittsburgh-biomolecule-neutralize/
-
- Aug 2020
-
www.nature.com www.nature.com
-
Hoffmann, M., Mösbauer, K., Hofmann-Winkler, H., Kaul, A., Kleine-Weber, H., Krüger, N., Gassen, N. C., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature, 1–5. https://doi.org/10.1038/s41586-020-2575-3
-
- Jul 2020
-
www.sciencedirect.com www.sciencedirect.com
-
Sun, J., Zhuang, Z., Zheng, J., Li, K., Wong, R. L.-Y., Liu, D., Huang, J., He, J., Zhu, A., Zhao, J., Li, X., Xi, Y., Chen, R., Alshukairi, A. N., Chen, Z., Zhang, Z., Chen, C., Huang, X., Li, F., … Zhao, J. (2020). Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. Cell. https://doi.org/10.1016/j.cell.2020.06.010
-
-
www.frontiersin.org www.frontiersin.org
-
Zhou, Q., Chen, V., Shannon, C. P., Wei, X.-S., Xiang, X., Wang, X., Wang, Z.-H., Tebbutt, S. J., Kollmann, T. R., & Fish, E. N. (2020). Interferon-α2b Treatment for COVID-19. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.01061
-
- Jun 2020
-
www.theatlantic.com www.theatlantic.com
-
Zhang, S. (2020, April 8). The Best Hopes for a Coronavirus Drug. The Atlantic. https://www.theatlantic.com/science/archive/2020/04/what-coronavirus-drug-will-look-like/609661/
-
-
www.biorxiv.org www.biorxiv.org
-
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., Hagglof, T., Oliveira, T. Y., Viant, C., Hurley, A., Hoffmann, H.-H., Millard, K. G., Kost, R. G., Cipolla, M., Gordon, K., … Nussenzweig, M. C. (2020). Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals [Preprint]. Immunology. https://doi.org/10.1101/2020.05.13.092619
-
- May 2020
-
www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
-
Wang, C., Li, W., Drabek, D. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 11, 2251 (2020). https://doi.org/10.1038/s41467-020-16256-y
-
-
www.thelancet.com www.thelancet.com
-
Lipsitch, M., Perlman, S., & Waldor, M. K. (2020). Testing COVID-19 therapies to prevent progression of mild disease. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(20)30372-8
-
- Apr 2020
-
www.thelancet.com www.thelancet.com
-
Mullard, A. (2020). Flooded by the torrent: The COVID-19 drug pipeline. The Lancet, 395(10232), 1245–1246. https://doi.org/10.1016/S0140-6736(20)30894-1
-
- Mar 2018
-
analesdequimica.es analesdequimica.es
-
Estas nanopartículas metálicas poseen un gran potencial en aplicaciones biomédicas como agente bactericida, fungicida, antiviral o cicatrizante.
Una parte en la idea del proyecto funciona en ayudar a crecer a las plantas protegiéndolas de las bacterias u hongos que puedan dañarlas y el hecho que estas partículas sirvan de fungicidas apoyan el hecho de la investigación Notar: El comentario se hace aquí pues en el documento no se pude hacer
-